EUMETSAT
14.12.2022 10:45:38 CET | Business Wire | Press release
Tonight’s launch of a highly advanced meteorological satellite from, Kourou, French Guiana, heralds the start of a new era for weather forecasting in Europe, EUMETSAT Director-General Phil Evans said.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005463/en/
MTG-I1 is successfully launched on an Ariane-5 rocket from Kourou, French Guiana (Photo: EUMETSAT)
The satellite, MTG-I1, is the first of a new generation of meteorological satellites carrying more advanced and precise instruments for monitoring and forecasting severe weather events such as storms, lightning, fog and wildfires.
It was successfully launched on an Ariane-5 rocket at 21:30 CET and is on its way to its correct orbit, 36,000km above the Equator.
“MTG-I1 will generate images of Europe and Africa every 10 minutes, faster than has been possible up until now, and in higher resolution, more precise detail,” Evans said.
“This data will help meteorologists meet one of their main challenges – timely and accurate forecasts of rapidly developing severe weather events – so that citizens, first responders and civil authorities can take appropriate action.
“The satellite’s lightning imager will continuously map lightning flashes between clouds and from clouds to the ground, which is a first for Europe with significant community and aviation industry safety benefits.”
MTG-I1 – full name Meteosat Third Generation – Imager 1 – will undergo a 12-month commissioning phase, in which its instruments will be calibrated and the data they produce validated, before becoming operational.
It will be operated from EUMETSAT’s headquarters in Darmstadt, Germany.
“Meteosat Third Generation is a European success story,” Evans said. “No European nation could afford to develop and operate such a system on its own. By combining the resources of our 30 member states, including their scientific and technical expertise, we are able to bring about a new era in weather and climate monitoring.”
More information about MTG-I1 can be found here.
Brochure containing facts and figures and other information about the MTG system can be found here.
The full Meteosat Third Generation constellation will comprise two imaging satellites and, for the first time, a sounding satellite. MTG – Sounder 1, is expected to be launched in 2024.
MTG-I1 was built by Thales Alenia Space under contract by the European Space Agency (ESA). ESA is responsible for procuring the satellites from industry fulfilling EUMETSAT’s requirements.
Thales Alenia Space Cannes is the prime industrial partner for the development of the MTG-I satellites. TAS works in close cooperation with:
• OHB-Bremen, which assembled, integrated and tested the platform
• LEONARDO in Italy, which provided the Lightning Imager instrument
• Thales Alenia Space Italy, which delivered the Data Collection and GEO SAR instruments
• Thales Alenia Space Cannes also integrated the Flexible Combined Imager.
For more information, visit the EUMETSAT website.
About EUMETSAT
EUMETSAT, Europe’s meteorological satellite agency, monitors the weather and climate from space. Based in Darmstadt, Germany, EUMETSAT provides its 30 member states with meteorological imagery and data that are essential for keeping their communities safe and for the benefit of critical sectors of their economies.
Three Meteosat Second Generation satellites in geostationary orbit deliver continuous observations of fast developing severe weather events over Europe, Africa and the Indian Ocean. The first of the Meteosat Third Generation satellites was launched in December 2022 and will undergo 12 months’ in-orbit commissioning. Two polar-orbiting Metop satellites provide data of pivotal importance for forecasts up to 10 days ahead. The first of the second-generation Metop satellites is expected to be launched in 2025.
EUMETSAT’s archive of satellite observations over more than 40 years provides climate scientists around the world with long-term, homogenous data necessary for monitoring climate change.
EUMETSAT is a key partner in the European Union’s Copernicus Earth observation programme. It operates the Copernicus Sentinel-3 and -6 ocean-monitoring missions, and will operate the upcoming CO2M mission, to monitor carbon dioxide emissions. EUMETSAT will fly the Copernicus Sentinel-4 and -5 missions on board its own MTG and Metop-SG satellites. Data from these Sentinels, and EUMETSAT’s own missions, are provided to the Copernicus climate, atmosphere monitoring and marine environment services. Along with European Space Agency and the European Centre for Medium-Range Weather Forecasts, EUMETSAT is a partner in the EU’s DestinE initiative, creating digital twins of the entire Earth system.
Together with NASA, NOAA, the EU, ESA and with support from the French Space Agency, CNES, EUMETSAT is a partner in the Jason and Copernicus Sentinel-6 ocean-monitoring missions.
EUMETSAT cooperates with agencies around the world, securing additional satellite data of benefit to weather forecasting and climate monitoring.
EUMETSAT’s 30 member states are: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005463/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom